MacroGenics to Participate in Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
MacroGenics (MGNX) PT Raised to $24 at BTIG, 'Discussions with Physicians Increase our Confidence in Vobra Duo’s Profile'
March 4, 2024 5:02 AM ESTBTIG analyst Kaveri Pohlman raised the price target on MacroGenics (NASDAQ: MGNX) to $24.00 (from $12.00) while maintaining a Buy rating.
The analyst comments "We are increasing our PT to $24 from $12 based on our recent conversations with KOLs who remain excited about vobra duos potential in prostate cancer. Our KOL interactions suggest that the data... More
